Phenotypeca Ltd expands its Board of Directors, welcoming Simon Chalk as their new Non-Executive Director
Progressive new start-up, Phenotypeca Ltd, is delighted to announce that they have expanded their Board of Directors with Simon Chalk being appointed as a Non-Executive Director at the end of December. Simon will play a significant role in defining Phenotypeca’s business growth strategy.
Simon joins Phenotypeca with over 20 years industry experience, having worked with some of the biggest biopharmaceutical manufacturing organisations in the world. After obtaining an engineering degree, Simon went on to become a management consultant with specific focus on the biopharmaceutical manufacturing supply chain area.
In 2002, Simon founded Biopharmaceutical Consulting and advised on a number of significant facility start up projects. In 2009 he was a founder of BioPhorum, a leading industry collaboration group, which has now become the most trusted environment for senior leaders from the biopharmaceutical industry to openly share and discuss emerging trends and challenges facing the industry. Simon also has strong skills as a facilitator and consultant, turning BioPhorum into a highly successful business, culminating in a private equity deal in 2018.
Commenting on Simon’s appointment, Keith Williams, Phenotypeca’s Founder and Managing Director said, “I have known Simon for more than 15 years and his professionalism, coupled with his incisive and direct approach, will be invaluable in helping to shape Phenotypeca as we grow as a company, his input to the strategy will bring significant benefits. Simon brings a wealth of experience as well as a keen interest in business development, which is key to our revenue mix in 2021 onwards. I look forward to working with Simon on the commercialisation of the excellent science we have done until now.”
Phenotypeca are leading the way in developing manufacturing technology for therapeutic proteins and exploring production strain phenotypes through a mix of expertise and world-leading technology, working to create and own yeast synthetic biology solutions to make any proteins, but initially, vaccines, diagnostics and other recombinant proteins.
The expansion to their board is an indication of the dedication Phenotypeca has to growing the business significantly over the coming years. Having experienced rapid expansion since the company was founded, there is a clear desire to keep that level of growth moving forward.